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Background/Aims.A r t e r i a ls t i ﬀness is an independent risk factor for cardiovascular morbidity and mortality. This study was
conducted to determine the eﬀect of olmesartan (OLM) and azelnidipine (AZL) on arterial stiﬀness using the cardio-ankle
vascular index (CAVI), which is a novel blood pressure (BP)-independent marker for arterial stiﬀness in hypertensive patients.
Methods. Fifty-two consecutive hypertensive patients were randomly assigned either to a group treated with OLM monotherapy
or to a group treated with OLM and AZL combination therapy. Clinical and biological parameters were measured before and 12
months after the start of this study. Results. Both therapies signiﬁcantly and similarly reduced BP, augmentation index, and plasma
aldosterone levels. The combination therapy signiﬁcantly decreased CAVI and serum low-density lipoprotein (LDL-C) levels
and these reductions were signiﬁcantly greater than those produced with monotherapy. No signiﬁcant diﬀerences in metabolic
parameters were observed between the two therapies. Conclusion. The combination therapy with OLM and AZL had beneﬁcial
eﬀects on arterial stiﬀness assessed by CAVI, LDL-C, and metabolism, despite the similar BP reduction, compared with OLM
monotherapy. Since these markers are known to inﬂuence the future risk of cardiovascular events, combination therapy with
OLM and AZL could be a useful choice for treating hypertensive patients.
1.Introduction
Arterial stiﬀness is an important risk factor for cardio-
vascular morbidity and mortality [1] and can be assessed
using several methods including pulse pressure (PP), the
augmentation index (AI), and pulse wave velocity (PWV).
These parameters are readily determined on an outpatient
basis and are well correlated with the risk of cardiovascular
events [1–3]. The cardioankle vascular index (CAVI) is a
novel marker of arterial stiﬀness that is calculated from the
PWV and adjusted according to the BP values. Therefore,
CAVIismoreindependentoftheBPeﬀectthanconventional
markers [4]. In addition, CAVI has been shown to be a
biomarkerfortheevaluationoftheseverityofarterialﬁbrosis
with higher sensitivity and speciﬁcity than PWV [4].
Both experimental data and clinical evidence suggest
that the renin-angiotensin system (RAS) contributes to
the pathogenesis of a number of cardiovascular diseases.
Angiotensin II type 1 receptor blockers (ARBs) are currently
some of the most wildly used antihypertensive drugs. ARBs
reduceBPandalsoaﬀectcardiovascularpropertiestoprotect
heart and kidney function [5]. We have demonstrated
that losartan, candesartan, and telmisartan improve arterial
stiﬀness as assessed by CAVI [6–8]. Olmesartan (OLM)
signiﬁcantly decreases CAVI in patients with hypertension
and diabetes [9, 10], but whether it is more eﬀective alone2 International Journal of Hypertension
than together with azelnidipine (AZL) treatment remains
uncertain.
Theaimofthisstudywastoevaluatetheprotectiveeﬀects
of OLM and add-on AZL on arterial stiﬀness in patients
with essential hypertension. Arterial stiﬀness was assessed by
measuringCAVI,theaugmentationindex(AI),andthemax-
imum of the carotid intima-media thickness (MAX-IMT).
2. Patientsand Methods
2.1. Study Population and Design. The subjects of the present
study were 52 consecutive hypertensive patients with arte-
rial stiﬀness and untreated hypertension or uncontrollable
hypertension treated with medications other than RAS
inhibitors. In patients without comorbid illness, hyperten-
sion was deﬁned as a clinic systolic BP of >140mmHg at any
time and/or a clinic diastolic BP of >90mmHg at any time
and/or a systolic BP of >130mmHg in the morning and/or a
diastolic BP of >85mmHg in the morning. In patients with
diabetes mellitus and chronic kidney disease, hypertension
was deﬁned as a clinic systolic BP of >130mmHg at any time
and/or a clinic diastolic BP of >80mmHg at any time. In
patients with metabolic syndrome, hypertension was deﬁned
as a clinic systolic BP of >130mmHg at any time and/or a
clinic diastolic BP of >85mmHg at any time.
All of the patients were randomly assigned to either a
group treated with OLM alone (monotherapy group) or a
group treated with OLM combined with AZL (combination
therapygroup).ThetargetBPwasdeﬁnedas<130/85mmHg
in patients without any complications and <130/80mmHg
in patients with diabetes mellitus, chronic kidney disease,
or metabolic syndrome. Patients in the monotherapy group
wereﬁrsttreatedwith20mg/dayofOLMfor4weeks,andthe
dose of the OLM was subsequently titrated up to 40mg/day.
IfthetargetBPwasnotachieved,additionalantihypertensive
medications other than RAS inhibitors and calcium channel
blockers were added. Patients treated with combination
therapy were ﬁrst treated with 20mg/day of OLM for 4
weeks, and 16mg/day of AZL was subsequently added.
The dose of the OLM was increased up to 40mg/day
until the target BP was attained. Additional antihypertensive
agents other than RAS inhibitors and calciumchannel block-
ers were further added unless the BP fell below the target
BP despite treatment with 40mg/day of OLM combined
with 16mg/day of AZL. Clinical and biological parameters
were measured before and 12 months after the start of this
study. During the study period, previous medications and
therapies other than antihypertensive drugs were continued.
The study was approved by the Review Board of Keio
University Medical School Hospital and written informed
consent was obtained from every subject.
Serum levels of creatinine (Cr), estimated glomerular
ﬁltration rate (eGFR), cystatin C, potassium (K), uric acid
(UA), triglyceride (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), gly-
coalbumin (GA), plasma levels of atrial natriuretic peptide
(ANP), brain natriuretic peptide (BNP), the active renin
concentrations (ARC), and aldosterone were measured in
venous blood samples. The albumin creatinine ratio (ACR)
was measured in urinary samples drawn on the morning
after an overnight fast on the same days as the ankle-
brachial index (ABI), cardioankle brachial index (CAVI),
augmentation index (AI), and BP measurements and the
maximum of carotid intima-media thickness (MAX-IMT)
measurements were performed.
2.2. Ambulatory Blood Pressure Monitoring. An oscillom-
etric-based device (TM-2431; A&D Co., Tokyo, Japan) was
usedtoperform24-hourambulatoryBPmonitoring.TheBP
wasmeasuredevery30minutesduringtheday(between6:00
AM and 10:00 PM) and every 60 minutes during the night
(between 10:00 PM and 6:00 AM). The mean values and the
standard deviations of the ambulatory BP for each subject
were calculated for a 24-hour period. The standard deviation
of the ambulatory BP values was recorded as the variability
of ambulatory BP in this study. The nocturnal decrease in
BP was calculated as the average systolic BP during the day
minus the average systolic BP during the night. The morning
BP surge was calculated as the highest systolic BP during the
ﬁrst 2 hours afterwaking minus the lowest systolic BP during
the night.
2.3. Cardioankle Vascular Index. T h eC A V Iw a sm e a s u r e d
using a VaSera VS-1000 vascular screening system (Fukuda
Denshi Co. Ltd., Tokyo, Japan), as described previously [11].
Cuﬀs were applied to bilateral upper arms and ankles, with
the subjects lying in a supine position and holding their
headsalongthemidline.ECGelectrodeswereplacedonboth
wrists, and a microphone for detecting heart sounds was
placed over the sternum. The patients rested in this supine
position for at least 10 minutes before the start of monitor-
ing. The CAVI was calculated using the following formula:
CAVI = a
 2ρ
ΔP

×ln

Ps
Pd

PWV2

+b,( 1 )
where, Ps is the systolic blood pressure, Pd is the diastolic
blood pressure, ΔP is Ps −Pd, ρ is blood density, and a and b
are constants.
2.4. Augmentation Index. T h eA Iw a sm e a s u r e du s i n g
an automated tonometric device (HEM-9000AI; Omron
Healthcare Co., Ltd., Kyoto, Japan), as described previously
[7]. Peripheral pressure waveforms were recorded over 30
seconds from the radial artery at the wrist with the subjects
in a sitting position after resting for at least 5 minutes. The
AI was calculated using the following formula
AI =

late systolic BP − diastolic BP (DBP)


systolic BP −DBP
 ×100 (%).
(2)
2.5. Albumin Creatinine Ratio (ACR). ACR was evaluated
on the basis of the mean albumin-to-creatinine ratio in
three nonconsecutive overnight urine samples. The uri-
nary concentrations of albumin and creatinine were deter-
mined using a turbidimetric immunoassay with a Superior-
Microalbuminkit(DPCCo.,Tokyo,Japan)andwiththeJaﬀ´ e
reaction using an autoanalyzer.International Journal of Hypertension 3
2.6. Carotid Intima-Media Thickness. Ultrasonography B-
mode imaging of the carotid artery was performed using
a PowerVision 6000 machine (Toshiba, Tokyo, Japan) at a
transducerfrequencyof7.5MHz.Eachsubjectwasexamined
whileinasupineposition.Upto4cmofthecommoncarotid
artery and the carotid bulb were scanned bilaterally using
longitudinal and transverse projections. The images were
focused on the far wall of the artery. Intima-media thickness
(IMT) was deﬁned as the distance between the leading edge
of the lumen-intima interface and the leading edge of the
media-adventitia interface of the far wall. The greatest IMT
value in the bilateral longitudinal projections was recorded
as the MAX-IMT. All measurements were performed under
blind conditions. The mean intraobserver and interobserver
coeﬃcients of variation for the maximum IMT were 4.3%
and 4.7%, respectively.
2.7. Statistical Analyses. Analyses were performed using
Microsoft Oﬃce Excel 2007 and StatView 5.0. software
(SAS Institute Inc., Cary, NC, USA). Fisher’s exact test was
used to analyze sex and the frequency of diabetes mellitus,
smoking, and the use of statins. The Mann-Whitney U test
was used to analyze the age and body mass index. The
changes in the biological parameters were analyzed using a
Studentt-testandatwo-wayanalysisofvarianceforrepeated
measures combined with Tukey-Kramer posthoc tests. The
contributions of changes in variables to changes in CAVI
were tested using a regression analysis and an analysis of
covariance. A P value < .05 was considered signiﬁcant. Data
are presented as the means ± SEM.
3. Results
No signiﬁcant diﬀerences were observed in the baseline
patient characteristics between the monotherapy group and
the combination therapy group, with the exception of the
serum K level (Table 1).
Duringthe12-monthtreatmentperiod,theclinicsystolic
BP, the clinic diastolic BP, the 24-hour ambulatory systolic
BP, the 24-hour ambulatory diastolic BP, the daytime systolic
BP, the daytime diastolic BP, and the nighttime systolic
BP decreased signiﬁcantly both after the monotherapy and
combination therapy, although no signiﬁcant diﬀerence was
observed between the two groups (Table 2). The night-
time diastolic BP decreased signiﬁcantly after combina-
tion therapy whereas it did not change signiﬁcantly after
monotherapy. The nocturnal decrease reduced signiﬁcantly
after monotherapy whereas it did not change signiﬁcantly
after combination therapy. No signiﬁcant changes in the
morning SBP surge or the SBP variability were seen during
the 12-month observation period in either group.
Figure 1 shows the changes in primary outcomes includ-
ing ACR, ANP, BNP, ABI, MAX-IMT, and arterial stiﬀness
as assessed by CAVI and AI in both groups. The CAVI
decreased signiﬁcantly from 8.4 ± 0.2 to 7.8 ± 0.2 after
combination therapy, whereas it did not change signiﬁcantly
after monotherapy. The reduction after the combination
therapy was signiﬁcantly greater than the monotherapy.
The AI decreased signiﬁcantly after both monotherapy and
combinationtherapy,from83.8 ±2.8to71.9 ±3.7,andfrom
75.2 ± 4.3 to 68.8 ± 3.3, respectively. The ACR, ANP, BNP,
and MAX-IMT did not change signiﬁcantly in either group.
During the 12-month observation period, the serum
LDL-C level decreased signiﬁcantly from 127 ± 6t o1 0 9±
8mg/dL after combination therapy whereas a signiﬁcant
change was not observed after monotherapy (Figure 2).
The reduction after combination therapy was signiﬁcantly
greater than the monotherapy. The plasma aldosterone
level decreased signiﬁcantly after both monotherapy and
combinationtherapy,from205 ±23to155 ±20pg/dL,from
194 ± 18 to 125 ± 9pg/dL, respectively, but no signiﬁcant
diﬀerence was observed between the two groups.
During the 12-month observation period, the reduction
in CAVI, ABI, and serum LDL-C level was signiﬁcantly
greater after the combination therapy than the monotherapy
after adjustment by the baseline value (Figures 3 and 4).
An ANCOVA analysis to examine whether the changes
in the LDL-C, plasma aldosterone, ABI, AI, clinical BP, 24-
h BP, daytime BP, and nighttime BP aﬀected the change in
CAVIduringthecombinationtherapy(Table 3).Thechanges
in the ABI and clinic SBP contributed signiﬁcantly to the
decrease in CAVI after combination therapy.
4. Discussion
The present study demonstrates that OLM plus AZL signif-
icantly improve the CAVI in hypertensive patients, which
reﬂects arterial stiﬀness. Although the reduction in the CAVI
in the combination therapy group was correlated with clinic
SBP,thebeneﬁcialeﬀectofOLMandAZLonarterialstiﬀness
was independent of BP changes. There was no signiﬁcant
diﬀerence in the reduction of brachial systolic BP between
the two treatments. It has been shown that the combination
of OLM and AZL has beneﬁcial eﬀects on the properties of
the cardiovascular system. Stimulation of the Angiotensin II
type1receptorresultsinstimulationofL-typecalciumchan-
nels and induces the inﬂux of extracellular calcium through
calcium channels. This calcium inﬂux results in a sustained
elevation of intracellular calcium [12]. The L-type calcium
channel blocker (CCB) AZL enhances the eﬀect of ARBs
on vascular remodeling independently of blood pressure
[13]. Moreover, AZL has been implicated in augmenting the
inhibitory eﬀect of ARB compared with other L-type CCBs
such as nifedipine and amlodipine [14]. Coadministration
of AZL and OLM synergistically blunts oxidative stress partly
through the inhibition of Akt activity and exerts antiathero-
genic actions by inhibiting VSMC migration and vascular
remodeling. Combination therapy has a beneﬁcial eﬀect
on central systolic BP and arterial stiﬀness, and enhances
the eﬀects of monotherapy with these drugs in treating
atherosclerosis [14–17]. The combination of AZL with OLM
acts to prevent hypertensive heart failure with preserved
systolic function in a rat model of this disease. Combination
therapy produces a greater reduction in cardiac ﬁbrosis by
inhibiting the increase in elastolytic activity induced by acti-
vation of NADPH oxidase [18, 19]. Simultaneous treatment
with exercise and OLM plus AZL produces renal protective
eﬀects in the rat model. This suggests that the treatment may4 International Journal of Hypertension
Table 1: Patient characteristics at baseline.
Characteristics Olmesartan Olmesartan + Azelnidipine P
Number 26 26 .999
Age (yr) 54.1 ±2.25 1 .7 ±2.0 .423
Male gender (n) 21 21 .495
BMI (kg/m2)2 3 .5 ±0.72 5 .8 ±0.9 .052
WC (cm) 84.8 ±2.39 1 .9 ±2.8 .053
DM (n) 3 1 .610
Smoker (n) 0 5 .051
Use of statin (n) 5 4 .999
Serum Cr (mg/dL) 0.92 ±0.05 0.91 ±0.06 .880
eGFR (mL/min/1.73m2)6 7 .7 ±2.97 2 .0 ±4.0 .390
Cystatin C (mg/dL) 0.74 ±0.03 0.80 ±0.06 .450
Serum K (mEq/L) 4.4 ±0.14 .2 ±0.1 .010
Serum UA (mg/dL) 6.6 ±0.36 .0 ±0.2 .345
Serum TG (mg/dL) 154 ±23 196 ±23 .209
Serum HDL-C (mg/dL) 60 ±45 3 ±3 .176
Serum LDL-C (mg/dL) 115 ±6 122 ±5 .451
GA (%) 14.6 ±0.31 4 .0 ±0.3 .173
ANP (pg/mL) 29.8 ±5.12 8 .0 ±3.2 .758
BNP (pg/mL) 19.8 ±6.92 4 .1 ±11.3 .755
Plasma ARC (pg/mL) 9.6 ±1.51 5 .6 ±4.3 .201
Plasma aldosterone (pg/mL) 205 ±16 209 ±21 .866
UAE (mg/gCr) 27.4 ±10.93 7 .4 ±13.8 .572
Clinic SBP (mmHg) 159 ±2 166 ±5 .247
Clinic DBP (mmHg) 102 ±8 105 ±3 .444
24-h SBP (mmHg) 144 ±2 145 ±3 .772
24-h DBP (mmHg) 90 ±19 0 ±2 .766
Daytime SBP (mmHg) 148 ±2 149 ±3 .732
Daytime DBP (mmHg) 92 ±19 2 ±2 .769
Nighttime SBP (mmHg) 130 ±3 128 ±3 .608
Nighttime DBP (mmHg) 83 ±28 0 ±2 .297
Nocturnal decrease (mmHg) 17 ±22 0 ±3 .436
Morning surge (mmHg) 29 ±33 8 ±4 .090
SBP variablity (mmHg) 20 ±12 2 ±1 .178
ABI 1.07 ±0.04 1.11 ±0.01 .386
CAVI 7.8 ±0.48 .3 ±0.2 .192
AI (%) 81.0 ±2.57 8 .6 ±3.1 .563
Mean IMT (mm) 0.9 ±0.10 .9 ±0.1 .797
Data are the means ± SEM. BMI, body mass index; WC, waist circumference; DM, diabetes mellitus; Cr, creatinine; eGFR, estimated glomerular
ﬁltration rate; K, potassium; UA, uric acid; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; GA,
glycoalbumin; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; ARC, active renin concentration; UAE, urinary albumin excretion; SBP, systolic
blood pressure; DBP, diastolic blood pressure; ABI, ankle-brachial index; CAVI, cardioankle vascular index; AI, augmentation index; IMT, intima-media
thickness.
aﬀect macrophage inﬁltration to the glomerulus, ﬁbroblast
accumulation in the glomerulus, mesangial activation, and
podocyte diﬀerentiation [20]. Combination therapy protects
against cyst enlargement in polycystic kidney disease by
suppressing interstitial inﬂammation, ﬁbrosis, and oxidative
stress through upregulating eNOS expression during the
courseofthedisease[21].Takentogether,thecombinationof
OLM plus AZL provides additional cardiovascular protective
eﬀectsonarterialstiﬀnessresultinginanimprovementinthe
CAVI. Since arterial stiﬀness is a powerful and independent
risk factor for mortality in cardiovascular events, OLM plus
AZL could be a ﬁrst-line antihypertensive drug [22].
The AI is another marker of arterial stiﬀness and reﬂects
the central aortic pressure [23, 24]. Vascular stiﬀening causes
an increase in the amplitude and early return of the reﬂected
waveduringsystole,withaugmentationofthecentralsystolic
BP and a resultant increase in AI [25]. We have shown that
ARBs decrease the AI [7, 8] but there has not been any prior
study focusing on the eﬀect of OLM on AI. In the present
study, OLM produced a reduction in the AI whereas AZL hasInternational Journal of Hypertension 5
Table 2: Changes in blood pressure during the study period.
Therapy Olmesartan Olmesartan + Azelnidipine P
Baseline 12 months Baseline 12 months Between therapies
Clinic SBP 157 ± 2 141 ± 3∗ 165 ± 6 143 ±4∗ .430
Clinic DBP 100 ± 28 7 ± 3∗ 106 ± 49 1 ±3∗ .813
24-h SBP 144 ± 3 129 ± 3∗ 147 ± 4 134 ±4∗ .726
24-h DBP 90 ± 28 1 ± 2∗ 92 ± 28 2 ±2∗ .779
Daytime SBP 149 ± 4 133 ± 3∗ 152 ± 4 138 ±4∗ .708
Daytime DBP 93 ± 98 4 ± 2∗ 94 ± 38 5 ±2∗ .820
Nighttime SBP 128 ± 5 113 ± 3∗ 129 ± 4 116 ±5∗ .852
Nighttime DBP 81 ± 47 2 ± 28 3 ± 27 2 ±2∗ .684
Nocturnal decrease 17 ± 29 ± 2∗ 20 ± 31 5 ±3 .472
Morning surge 33 ± 53 2 ± 34 0 ± 53 8 ±4 .921
SBP variability 21 ± 22 1 ± 22 3 ± 12 2 ±2 .738
Units are mmHg. Data are the means ± SEM. SBP, systolic blood pressure; DBP, diastolic blood pressure. ∗P<. 05 versus the baseline value.
Table 3: Eﬀects of percent changes in LDL-C, plasma aldosterone, ABI, AI, clinical BP, 24-h BP, daytime BP, and nighttime BP on percent
changes in CAVI after combination therapy.
ANCOVA Coeﬃcient SE t-value P
Intercept −17.930 9.220 −1.945 .0696
ΔLDL 0.547 10.422 0.052 .9588
Intercept −48.479 26.262 −1.846 .0878
Δplasma aldosterone 30.080 27.760 1.084 .2982
Intercept −0.061 0.021 −2.893 .0106
ΔABI −0.052 0.024 −0.479 .0441
Intercept −7.475 3.985 −1.876 .0852
ΔAI −1.744 4.932 −0.354 .7298
Intercept −8.027 7.571 −1.060 .3048
Δclinic SBP 21.792 8.558 2.546 .0216
Intercept −10.428 4.509 −2.313 .0344
Δclinic DBP 6.750 5.096 1.325 .2039
Intercept −7.595 4.425 −1.717 .1066
24h SBP 8.584 4.896 1.753 .1000
Intercept −8.952 3.175 −2.819 .0129
Δ24h DBP 1.042 3.513 0.297 .7708
Intercept −9.199 4.478 −2.054 .0578
Δdaytime SBP 6.761 4.955 1.364 .1926
Intercept −9.811 3.172 −3.093 .0074
Δdaytime DBP −0.711 3.509 −0.203 .8422
Intercept −6.706 4.743 −1.414 .1778
Δnighttime SBP 9.909 5.248 1.888 .0785
Intercept −7.240 3.250 −2.228 .0416
Δnighttime DBP 5.993 3.596 1.666 .1164
LDL-C, low-density lipoprotein cholesterol; ABI, ankle-brachial index; AI: augmentation index; BP: blood pressure; CAVI: cardioankle vascular index;
ANCOVA: analysis of covariance; SE: standard error.6 International Journal of Hypertension
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Figure 1: Cardioankle vascular index (CAVI), augmentation index (AI), ankle-brachial index (ABI), maximum of intima-media thickness
(MAX-IMT),urinary albumin to creatinine ratio (ACR),serum atrial natriuretic peptide (ANP),and serum brain natriuretic peptide (BNP)
at baseline and after 12 months of treatment with olmesartan monotherapy (open circles) or combination therapy with olmesartan and
azelnidipine (closed circles). ∗P<. 05 versus the baseline value. †P<. 05 versus the olmesartan monotherapy.
been previously shown to cause a signiﬁcant reduction in AI
in combination with ARBs [26]. This was conﬁrmed in the
present study indicating that combination therapy results in
a reduction in AI. Since there was not any diﬀerence in the
decrease in the AI between the two therapies, the reduction
could be explained by the vascular protective eﬀects of the
OLM.
In this study a signiﬁcant reduction in the serum LDL-
C levels after the combination therapy was observed. This
improvement in the serum LDL-C levels can be attributed
to azelnidipine, since OLM monotherapy did not produce
a decrease in the serum LDL-C levels. A previous study
showed that the antioxidant eﬀect of azelnidipine may have
participated in the reduction of plasma malondialdehyde-
modiﬁed LDL (MDA-LDL) levels [27]. The antioxidant
eﬀectofAZLpossiblyparticipatedinthereductionofplasma
MDA-LDL levels [28, 29]. In this respect, combination
therapy would be preferable for hypertensive patients with
comorbid dyslipidemia.
In the present study, the metabolic parameters were not
signiﬁcantly altered in either treatment group. This conﬁrms
previous reports that show that the incidence of adverse
events is similar in the combination and the monotherapy
groups [30]. Thus, the present study also conﬁrmed the
metabolic safety of OLM and AZL.
Somelimitations ininterpreting theresultsofthepresent
study need to be recognized. These include that the trial
population was comparatively small and the observation
period was relatively short. A longer observation with a
larger number of subjects might more clearly elucidateInternational Journal of Hypertension 7
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Figure 2: Serum creatinine (Cr), estimated glomerular ﬁltration rate (eGFR), serum cystatin C, serum K, serum uric acid (UA),
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the beneﬁcial and adverse eﬀects of OLM and AZL. In
addition,prognosticeventswerenotexaminedinthepresent
study. Therefore, further studies are needed to conﬁrm the
beneﬁts and safety of OLM and AZL therapy.
Inconclusion,thecombinationtreatmentwithOLMand
AZL compared with OLM monotherapy produces beneﬁcial
eﬀects on arterial stiﬀness as assessed by CAVI, as well as by
the level of LDL-C, despite a similar reduction of BP. Since
these markers are known to inﬂuence the future risk for car-
diovascular events in hypertensive patients, the combination
ofOLMandAZLcouldwellbeareasonableantihypertensive
management for the treatment of hypertensive patients.
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